Comparison of Streptokinase and Heparin in Treatment of Isolated Acute Massive Pulmonary Embolism

Massive pulmonary embolism was confirmed by pulmonary arteriography in 23 patients. All were seen between 2 and 48 hours after the onset of embolism and none had pre-existing cardiorespiratory disease. Fifteen were treated with streptokinase and eight with heparin. Factors which might influence prognosis and rate of resolution were similar in the patients in each group, and there was no significant difference between the groups in terms of pretreatment haemodynamic or arteriographic findings. Haemodynamic and arteriographic findings after treatment for 72 hours provided an objective measurement of resolution, which was significantly greater in the streptokinase-treated patients. There was no mortality in either group, but treatment had to be changed in two heparin-treated patients because of clinical deterioration. The principal complication of treatment, seen more often in the streptokinase-treated patients, was bleeding from cut-down or operation sites.     

Streptokinase Therapy in Acute Major Pulmonary Embolism: Effectiveness and Problems

Eighteen patients with major pulmonary embolism were treated with streptokinase infused by a catheter or given intravenously. Fourteen showed clinical improvement and 12 out of 16 patients investigated showed definite angiographic improvement after 24 to 48 hours of treatment with streptokinase. The angiographic improvement following streptokinase contrasted with the lack of this in three patients after 24 hours of heparin treatment.Resolution following streptokinase therapy was most noticeable in patients treated shortly after a single embolic episode, and was least marked in those with recurrent embolism complicated by associated cardiac or pulmonary disease. Of the four patients who failed to improve, two died and two had pulmonary embolectomy and survived.The results suggest that streptokinase therapy is practicable provided that adequate laboratory control is available, and that it hastens early resolution in acute major pulmonary embolism.     

Comparison by Controlled Clinical Trial of Streptokinase and Heparin in Treatment of Life-threatening Pulmonary Embolism

Treatment with heparin or streptokinase was allocated randomly to 30 patients with life-threatening pulmonary embolism verified by angiography. Treatment was given for 72 hours and pulmonary angiography was repeated. There was significantly greater (P < 0·001) evidence of thrombolysis in those patients treated with streptokinase compared with those treated with heparin. The reduction of systolic and mean pulmonary arterial pressures was also significantly greater (P < 0·05 and P < 0·02 respectively) in the streptokinase group.Seven patients failed to complete 72 hours of the trial treatment: five successfully underwent pulmonary embolectomy. Six of these “failures” had initial pulmonary angiographic scores of 24 or more and systemic systolic blood pressure recordings of 100 mm Hg or less. Patients with these features should probably be considered for pulmonary embolectomy as the initial treatment.A febrile reaction commonly occurred in the streptokinase group; otherwise side effects were no more common than in the heparin group.     

急性肺栓塞常用检查方法及效果评价

肺动脉栓塞的诊断虽在临床工作中较少见到,但却是一种常见的致死性急症,却易被广大临床医务工作者所忽视。本文综述几种简单有效的检查方法,以提高急性PE的诊断率及便于及早治疗并降该病的病死率,并为进一步防治肺动脉栓塞提供参考依据。     

Comparison of the Effects of Streptokinase and Heparin on the Early Rate of Resolution of Major Pulmonary Embolism

The extent of early resolution of major pulmonary embolism observed in 10 patients after 24 hours of treatment with heparin was compared with that seen in 17 patients after 24 hours of treatment with streptokinase. The patients in the streptokinase group also received a loading dose of heparin and were treated with heparin by continuous infusion when their thrombin time returned to normal levels. All had pulmonary hypertension. Pulmonary embolism was classified as acute in the 10 patients in the heparin group. Seven of these patients showed no angiographic change, two showed slight improvement and one showed angiographic deterioration. There was a moderate and statistically insignificant fall in mean pulmonary arterial pressure and total pulmonary resistance. Fourteen of the 17 patients who were studied before and after streptokinase were classified as acute and three as subacute progressive major pulmonary embolism. Eight showed marked angiographic improvement, four moderate and two slight angiographic improvement. There was a moderate and statistically significant fall in the mean pulmonary arterial pressure and pulmonary vascular resistance. In addition, all seven patients in whom no angiographic improvement occurred during heparin therapy showed moderate or marked angiographic improvement after a further 24 hours of treatment with streptokinase. The results strongly suggest that streptokinase therapy accelerates thrombolysis in patients with acute major pulmonary embolism.     

Acute Cardiac Disorder or Pneumonia and Concomitant Presence of Pulmonary Embolism

Purpose

To determine the frequency of apparent acute pulmonary embolism (PE) and of concomitant disease in computed tomography pulmonary angiography (CTPA); to compare the frequency of PE in patients with pneumonia or acute cardiac disorder (acute coronary syndrome, tachyarrhythmia, acute left ventricular heart failure or cardiogenic shock), with the frequency of PE in patients with none of these alternative chest pathologies (comparison group).

Methods

Retrospective analysis of all patients who received a CTPA at the emergency department (ED) within a period of four years and 5 months.

Results

Of 1275 patients with CTPA, 28 (2.2%) had PE and concomitant radiologic evidence of another chest disease; 3 more (0.2%) had PE and an acute cardiac disorder without radiological evidence of heart failure. PE was found in 11 of 113 patients (10%) with pneumonia, in 5 of 154 patients (3.3%) with an acute cardiac disorder and in 186 of 1008 patients (18%) in the comparison group. After adjustment for risk factors for thromboembolism and for other relevant patient’s characteristics, the proportion of CTPAs with evidence of PE in patients with an acute cardiac disorder or pneumonia was significantly lower than in the comparison group (OR 0.13, 95% CI 0.05–0.33, p<0.001 for patients with an acute cardiac disorder, and OR 0.45, 95% CI 0.23–0.89, p = 0.021 for patients with pneumonia).

Conclusion

The frequency of PE and a concomitant disease that can mimic PE was low. The presence of an acute cardiac disorder or pneumonia was associated with decreased odds of PE.     

肺栓塞的诊治和预防策略

急性肺栓塞(PE)是一种心血管疾病突发事件,具有较高的发病率和死亡率。一旦发生PE,快速、有效的诊治是挽救PE患者生命的关键,但也是呼吸内科医生一直面临的挑战。尽管PE的诊断手段和评估方法已经取得了很大地进步,但由于PE患者临床表现的非特异性和诊断方法的多样、复杂性,如何采取及时、有效的诊治策略仍是呼吸内科医生面临的重要难题。与此同时,由于PE诊断困难,治疗风险大,也使其临床预防势在必行。鉴于此,本文综述了当前欧洲心脏病学会(ESC)等国际心血管研究机构发布的PE诊治指导方针和研究进展,为读者进一步认识和掌握PE快速、有效的诊治和预防策略提供参考。     

急性脑梗死的超早期治疗

目的 研究蛇岛牌精制蜊蛇抗栓毒抗检胶囊对急性离梗死的超早期治疗效果。方法 入选６０例急性患者（发病６￣８ｈ以内）,分成两组,每组３０例;治疗组给予蛇岛牌精制蛇抗栓酶３．０ｕ静脉滴注,１２ｈ１次,连用３天后,改为１．５ｕ静脉滴注,每日１ ,同时服用蛇毒抗 胶囊０．６ｇ（本院科研药品）,每日３次,治疗１５天;对照组给予东菱克栓酶１０ＩＵ,前５天每日１次,后１０天隔日１次,同时监测血液流变学。结果 治疗     

The Prevalence and Incidence of Atrial Fibrillation in Patients with Acute Pulmonary Embolism

Background

Symptomatic pulmonary embolism (PE) is a major cause of cardiovascular death and morbidity. Estimated prevalence and incidence of atrial fibrillation (AF) in developed countries are between 388–661 per 100,000, and 90–123 per 100,000 person-years respectively. However, the prevalence and incidence of AF in patients presenting with an acute PE and its predictors are not clear.

Methods

Individual patient clinical details were retrieved from a database containing all confirmed acute PE presentations to a tertiary institution from 2001–2012. Prevalence and incidence of AF was tracked from a population registry by systematically searching for AF during any hospital admission (2000–2013) based on International Classification of Disease (ICD-10) code.

Results

Of the 1,142 patients included in this study, 935 (81.9%) had no AF during index PE admission whilst 207 patients had documented baseline AF (prevalence rate 18,126 per 100,000; age-adjusted 4,672 per 100,000). Of the 935 patients without AF, 126 developed AF post-PE (incidence rate 2,778 per 100,000 person-years; age-adjusted 984 per 100,000 person-years). Mean time from PE to subsequent AF was 3.4 ± 2.9 years. Total mortality (mean follow-up 5.0 ± 3.7 years) was 42% (n = 478): 35% (n = 283), 59% (n = 119) and 60% (n = 76) in the no AF, baseline AF and subsequent AF cohorts respectively. Independent predictors for subsequent AF after acute PE include age (hazard ratio [HR] 1.06, 95% confidence interval [CI] 1.04–1.08, p<0.001), history of congestive cardiac failure (HR 1.88, 95% CI 1.12–3.16, p = 0.02), diabetes (HR 1.72, 95% CI 1.07–2.77, p = 0.02), obstructive sleep apnea (HR 4.83, 1.48–15.8, p = 0.009) and day-1 serum sodium level during index PE admission (HR 0.94, 95% CI 0.90–0.98, p = 0.002).

Conclusions

Patients presenting with acute PE have a markedly increased age-adjusted prevalence and subsequent incidence of AF. Screening for AF may be of importance post-PE.     

急性肺栓塞的心电图表现特点分析

目的:探讨急性肺栓塞的心电图表现特点,提高急性肺栓塞的诊断水平。方法:选取我院急诊收治的急性肺栓塞患者79例,进行床旁心电图多次动态检测,观察急性肺栓塞患者心电图的基本特点,分析心电图对急性肺栓塞的临床诊断意义。结果:在79例患者中,发生心电图改变者72例(91.14%),其中窦性心动过速者63例(79.74%),为最常见的心电图改变;Ⅰ导联S波较深者51例(64.56%);Tv1-v3倒置者45例(56.96%);Tv1-v2倒置者31例(39.24%);右束支传导阻滞改变者27例(34.17%);Tv1-v4倒置者18例(22.78%)。典型的肺栓塞SⅠQⅢTⅢ心电图表现少见,仅14例(17.72%),而心电图表现为QⅢTⅢ者49例(62.02%)。结论:急性肺栓塞的心电图改变具有非特异性和复杂多变性,临床医生应将心电图检查结果作为诊断依据之一,仍需结合患者的临床表现,进行综合分析判断,再给予合理诊断及时治疗,以改善急性肺栓塞患者的预后。     

Resolution of Pulmonary Embolism

To assess restoration of pulmonary perfusion after pulmonary embolism serial lung scans were carried out on 74 patients. Of these, one-third showed almost complete recovery, one-third improved, and the remainder either failed to improve or became worse. Perfusion was most rapidly restored in the first few days after the embolus and more slowly during the next two to three weeks.Untreated patients improved less often and had more new defects in perfusion than patients treated with anticoagulant therapy, no difference occurring in either the amount of improvement or in the rate of recovery of perfusion between patients treated with different anticoagulant regimens. There was evidence of further pulmonary emboli in 35% of treated patients, 82% of these occurring within two weeks of the initial embolus. Patients with defects in perfusion greater than 30% showed considerable improvement but recovered less well than those with smaller defects.